Utilizing Automated Breast Cancer Detection to Identify Spatial
  Distributions of Tumor Infiltrating Lymphocytes in Invasive Breast Cancer by Le, Han et al.
Utilizing Automated Breast Cancer Detection to
Identify Spatial Distributions of Tumor Infiltrating
Lymphocytes in Invasive Breast Cancer
Han Le1,+, Rajarsi Gupta2,3,*,+, Le Hou1, Shahira Abousamra1, Danielle Fassler3, Tahsin
Kurc2, Dimitris Samaras1, Rebecca Batiste3, Tianhao Zhao3, Alison L. Van Dyke4, Ashish
Sharma6, Erich Bremer2, Jonas S. Almeida5, and Joel Saltz2
1Department of Computer Science, Stony Brook University, Stony Brook, NY 11974, USA
2Department of Biomedical Informatics, Stony Brook Medicine, Stony Brook, NY 11794, USA
3Department of Pathology, Stony Brook University Hospital, Stony Brook, NY 11794, USA
4Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892, USA
5National Cancer Institute Division of Cancer Epidemiology & Genetics, Bethesda, MD 20892, USA
6Department of Biomedical Informatics, Emory University, Atlanta, GA 30322, USA
*Rajarsi.Gupta@stonybrookmedicine.edu
+these authors contributed equally to this work
ABSTRACT
Quantitative assessment of Tumor-TIL spatial relationships is increasingly important in both basic science and clinical aspects of
breast cancer research. We have developed and evaluated convolutional neural network (CNN) analysis pipelines to generate
combined maps of cancer regions and tumor infiltrating lymphocytes (TILs) in routine diagnostic breast cancer whole slide
tissue images (WSIs). We produce interactive whole slide maps that provide 1) insight about the structural patterns and spatial
distribution of lymphocytic infiltrates and 2) facilitate improved quantification of TILs. We evaluated both tumor and TIL analyses
using three CNN networks - Resnet-34, VGG16 and Inception v4, and demonstrated that the results compared favorably
to those obtained by what believe are the best published methods. We have produced open-source tools and generated a
public dataset consisting of tumor/TIL maps for 1,015 TCGA breast cancer images. We also present a customized web-based
interface that enables easy visualization and interactive exploration of high-resolution combined Tumor-TIL maps for 1,015
TCGA invasive breast cancer cases that can be downloaded for further downstream analyses.
Introduction
Among women worldwide, invasive breast cancer is the most common cancer and the second most common cause of cancer-
related death1, despite decreasing mortality rates in recent years due to early diagnosis and current therapeutic options
that significantly prolong survival. Invasive breast cancers are a heterogeneous category of disease phenotypes2, 3 that are
histologically classified into subtypes based on growth patterns; the expression of estrogen (ER), progesterone (PR), human
epidermal growth factor receptor 2 (HER2); and the Ki-67 proliferation index.
The role of tumor infiltrating lymphocytes (TILs) in invasive breast cancer has become increasingly important as a biomarker
that can predict clinical outcomes, as well as to predict treatment response in the neoadjuvant and adjuvant setting4–11. TILs
are a readily available biomarker and their evaluation is likely to expand with the emergence of immunotherapy. Elevated
concentrations of TILs in HER2-positive12 and triple-negative (ER-/PR-/HER2-)13 breast cancers are associated with prolonged
overall and disease-free survival; whereas elevated concentrations of TILs in luminal HER2-negative breast cancer have been
associated with poor overall survival4. TILs can also serve as a predictive biomarker since a significant part of the cytotoxic
effects of systemic chemotherapy and radiation-therapy are actually mediated by activating the immune system to kill cancer
cells instead of directly targeting the tumor cells14. Targeted therapies against HER2 and vascular endothelial growth factor
(VEGF) are mediated by both antibody-dependent and complement-mediated cytotoxicity in cancer cells through lymphocytes
and other immune cells in the tumor microenvironment15. Recent studies suggest potential for synergistic effects between
targeted and immune therapies in multiple disease sites16, 17.
Current practice routinely includes manual assessments of hematoxylin and eosin (H&E) stained tissue sections by
surgical pathologists to identify and classify invasive breast cancer. Such diagnostic evaluation provides insight about clinical
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management, treatment selection, survival, and recurrence. Since H&E tissue sections are readily available, there is a
sustainable opportunity to provide potentially actionable data about TILs without the need for additional tissue samples (e.g.,
immunohistochemical (IHC) testing). H&E also permit the interpretation of the lymphocyte infiltrate within and proximal
to the tumor in the context of histology to provide insight about the spatial relationships between tumor regions and TILs.
The published guidelines for the histologic assessment of TILs in invasive breast cancer18–20 require pathologists to select
the region of tumor and to delineate stromal areas in order to assess the percentage of TILs (%TILs) in stromal regions as a
continuous variable from 0-100% within the boundaries of the entire tumor that is used to classify the lymphocyte infiltrate as
low, intermediate, and high, respectively.
However, this evaluation is intrinsically qualitative and often subject to inter-observer variability, so previous work as
articulated these concerns21 in an attempt to clearly state the need for automated methods to evaluate %TILs in H&E tissue
sections of breast cancer. Computationally calculating %TILs intrinsically provides spatial information about how TILs are
distributed in whole slide images (WSIs), where it is likely that the distinction between intratumoral and stromal TIL infiltrates
is important. While there have been some relatively small studies examining intratumoral and stromal TILs22, the predictive
power of the spatial distribution of TILs within tumor and tumor-associated stroma needs to be better elucidated. Automated
evaluation of TILs in H&E WSIs fundamentally requires tumor segmentation linked with the detection of lymphocyte infiltrates.
Automation of H&E tumor-TIL analyses will make it possible to carry out large-scale correlative studies that quantitatively
characterize TIL distributions in well-characterized clinical populations. Computer analysis of high-resolution images of whole
slide tissue specimens can enable a data driven and quantitative characterization of TIL patterns.
With the recent success of deep learning23 and the availability of public datasets24–27, several research groups have
proposed deep learning based algorithms to detect or segment cancer/tumor regions in breast cancer WSIs28–31. However, the
overall performance of previous methods was constrained due to the insufficient capacity of customized convolutional neural
networks28, 29 or the limited amount of training data30, 31. Hence, we proposed to use standard state-of-the-art deep learning
models with the usage of a large-scale dataset to detect invasive breast cancer regions in WSIs. Our experimental evaluation on
a public test set showed better results than the models in the previous works. Our study also combines tumor detection with
lymphocyte detection to identify TILs in a large number of WSIs which are publicly accessible for the breast cancer research
community.
We utilized a previously published deep learning method to detect lymphocytes in WSIs32. In this report, we combine
a breast tumor segmentation algorithm with lymphocyte detection to leverage the training data used in Saltz et al., 201832.
We developed a deep learning-based method to automate breast cancer detection at intermediate- to high-resolution in order
to generate detailed probability-based heat maps of the tumor bed. Our approach achieves an F1-score of 0.82, a positive
predictive value (PPV) of 79%, and negative predictive value (NPV) of 98% in terms of pixel-by-pixel evaluation in an unseen
and independent test dataset consisting of 195 TCGA WSIs. We then combined the breast cancer detection with results from a
published methods that utilizes deep learning to generate high-resolution TIL maps. The combined results represent regions
of Tumor with intra- and peritumoral TILs in 1,015 WSIs from the publicaly available The Cancer Genome Atlas (TCGA)
repository. We expect that the availability of high-resolution spatial Tumor-TIL maps will allow quantitative estimation and
characterization of the relationship between tumor cells and TILs. The ability to quantify and visualize the spatial relationships
between tumor and TILs can be a very practical and useful way to further elucidate intriguing observations in previous studies.
It will also further our collective understanding of the biological behavior of invasive breast cancers within the context of
cancer-immune interactions in the tumor microenvironment.
Results
Datasets
We used high-resolution WSIs from the Virtual Tissue Repository (VTR) Pilot Program operated through the Surveillance,
Epidemiology, and End Results (SEER: https://seer.cancer.gov/) cancer registry system and from The Cancer Genome Atlas
(TCGA: https://portal.gdc.cancer.gov/) to train and evaluate the deep learning models and to generate cancer region maps. The
training, validation, and test datasets consisted of image patches extracted from 102, 7, and 89 SEER WSIs, respectively. All of
the images were scanned at 400x magnification and manually segmented by an expert pathologist into cancer and non-cancer
regions using a web-based application33. Additionally, we evaluated the models using manual tumor region annotations in 195
TCGA WSIs (referred as here to Ttcga); this dataset had been generated by Cruz-Roa et al.29 and was publicly accessible. The
details of the training, validation and test datasets for tumor region segmentation are presented in Table 1. The trained models
were applied to 1,015 diagnostic WSIs from TCGA invasive breast cancer cases. The same set of WSIs was also analyzed
using the TIL classification models trained with data generated by Saltz et al.32. These data consisted of 86,154 and 653 image
patches for training and validation, respectively. We created a test dataset of 327 patches extracted from TCGA invasive breast
cancer WSIs to evaluate the trained models. The details of the training, validation, and test datasets for TIL classification are
presented in Table 2.
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Source Purpose ID WSIs (N) Patches (N) Positive (N) Negative (N)
SEER
Training D_tr 102 333,604 99,889 233,715
Validation D_val 7 10,224 4,953 5,271
Testing T_seer 89 - - -
TCGA Testing T_tcga 195 - - -
Table 1. Data statisitcs of the Breast Cancer dataset.
Source Purpose Patches (N) Positive (N) Negative (N)
TCGA
Training 86,154 21,773 64,381
Validation 653 295 357
Testing 327 174 153
Table 2. Data statistics of the Lymphocytes dataset provided in Saltz et al.32
Experiments
We evaluated multiple state-of-the-art deep learning networks, namely VGG1634, Resnet3435, and Inception-v436, for the
tasks of detecting and segmenting breast cancer regions and classifying TILs in WSIs. We used accuracy, F1-score, and area
under the ROC (Receiver Operating Characteristic) curve (AUC) as performance evaluation metrics. Accuracy is the ratio of
correct predictions to the total number of data elements in the ground truth dataset. Because a dataset is not always balanced
between classes, we used the F1-score that considers both precision and recall to compute a score. Mathematically, F1-score =
2*(precision*recall)/(precision + recall). Lastly, we used AUC to evaluate the prediction capability of our model at different
threshold settings. AUC shows the relationship between True Positive Rate (TPR) and False Positive Rate (FPR) of the model.
It is a widely used metric to assess model performance for binary classification tasks.
The best models (Tables 3 and 4) were applied to WSIs from 1,015 TCGA invasive breast cancers to generate what we
call prediction probability maps for cancer regions and TILs. A prediction probability map is constructed by partitioning a
WSI into N×N image patches. The image patches were analyzed by the trained model and were assigned a label probability
between 0.0 and 1.0. For cancer region segmentation, the label of a patch was either positive (i.e., the patch predicted to be
within or intersect a cancer region) or negative (i.e., the patch is predicted to be outside the cancer regions in the WSI). For TIL
classification, the label of a patch was either TIL-positive (i.e., the patch was predicted to contain lymphocytes) or TIL-negative.
The model assigned a value between 0.0 and 1.0 to each patch to indicate the predicted probability of the corresponding label.
We developed a Web-based application to visualize and interact with the prediction probability maps as heatmaps (please see
"Methods" section).
Evaluation of Cancer Detection Models
We trained three cancer detection and segmentation models, C-VGG16, C-Resnet34 and C-Incepv4, by using VGG16, Resnet34
and Inception-v4, respectively. We compared the performances of the models to each other as well as to a model that was
trained by a learning network called ConvNet, which was developed by Cruz-Roa et al.28, 29. ConvNet was originally trained on
a different training dataset, HUP and UHCMC/CWRU28. In order to use our training datasets, we implemented ConvNet using
Pytorch37 by precisely following the network description in the original paper28. We call our implementation ConvNet-ours.
We computed an average F1-score across all the test images by varying the threshold value from 0.0 to 1.0 in steps
of 0.01. At each threshold value, prediction probability maps were computed for the 195 test images by the model under
evaluation and the patch labels were assigned by thresholding the prediction probability maps by the threshold value. The
thresholded label maps and the ground-truth masks29 were then used to compute average F1-score, positive predictive value
(PPV), negative predictive value (NPV), true positive rate (TPR), true negative rate (TNR), false positive rate (FPR), and false
negative rate (FNR). Table 3 shows the performance comparison between our models, the original ConvNet model28, 29, and our
implementation of the ConvNet model (ConvNet-ours). We report the performance of ConvNet-ours both with and without
applying our post-processing step (please see "Methods" section), because no post-processing step was applied to the original
ConvNet model28, 29. Table 3 shows that the post-processing step improves the average F1-score from 0.75 to 0.77 and PPV
from 0.69 to 0.73. Moreover, ConvNet-ours slightly outperforms the original ConvNet model in all metrics. Figure 1 shows
prediction probability maps produced for a set of representative WSIs in Ttcga using the C-Resnet34 model. The shades of red
in the map images indicate how confident the model is that a patch is positive (i.e., patch in cancer region) or negative (patch
outside cancer region). A visual inspection of the maps and the respective WSIs showed that the model was able to detect and
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Method F1-score PPV NPV TPR TNR FPR FNR
ConvNet29 0.76 +− 0.20 0.72 +− 0.22 0.97 +− 0.05 0.87 +− 0.16 0.92 +− 0.08 0.08 +− 0.08 0.13 +− 0.16
ConvNet-ours 0.75 +− 0.18 0.69 +− 0.22 0.96 +− 0.09 0.87 +− 0.18 0.91 +− 0.09 0.09 +− 0.07 0.12 +− 0.16
ConvNet-ours∗ 0.77 +− 0.21 0.73 +− 0.23 0.97 +− 0.09 0.87 +− 0.23 0.92 +− 0.09 0.08 +− 0.09 0.13 +− 0.22
C-VGG16 0.80 +− 0.20 0.78 +− 0.20 0.97 +− 0.05 0.88 +− 0.21 0.94+− 0.06 0.06+−0.06 0.12+−0.21
C-Resnet34 0.82 +− 0.18 0.79 +− 0.20 0.98 +− 0.04 0.89 +− 0.18 0.95 +− 0.05 0.05 +− 0.05 0.11 +− 0.18
C-Incepv4 0.81+−0.19 0.79+−0.20 0.97+−0.05 0.88+−0.19 0.94+−0.06 0.06+−0.06 0.12+−0.19
Table 3. Performance comparison of the Cancer Detection task between the ConvNet29 and our models. ConvNet-ours: Our
implementation of the ConvNet29 that was trained on the SEER dataset and results were reported without applying the
post-processing method (please see "Methods" section for the post-processing method). ConvNet-ours∗: Our implemented
version of the ConvNet29 that was trained on SEER dataset and results were reported after applying post-processing method.
The last three rows are preformance of our CNNs. All models were trained on the SEER dataset (Dtr) and evaluated on 195
TCGA WSIs (Ttcga).
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Figure 1. Prediction map of representative slides from Dtcga. Figures A-D are WSIs with ground truth generated by our expert
pathologists. Figures E-H show the corresponding prediction heatmap generated by our Cancer detection algorithm,
C-Resnet34, prior to applying any aggregation methods. Figures I-L show the corresponding prediction map after applying
Max aggregation function with window size of 4 then applying threshold of 0.6 to exclude prediction scores that are less than
0.6. Figures M-P show results of our algorithm in terms of TP (green), FN (red), FP (yellow), and TN (blue) regions.
segment cancer regions faily well.
Evaluation of Lymphocyte Classification Models
We trained three lymphocyte detection models: L-VGG16, L-Resnet34, and L-Incepv4, using VGG16, Resnet34, and Inception-
v4, respectively. The training dataset32 contained only 2,912 image patches (out of 86,154) from invasive breast cancer WSIs.
We found that it resulted in more accurate classification models when a network was trained with all the training patches than
with only the invasive breast cancer patches. We tested the trained models with a set of image patches extracted from TCGA
invasive breast cancer WSIs. Table 4 shows the performance comparison between our models with the model developed in the
previous work32. Our new models consistently outperformed the model in the previous work in all of the performance metrics.
Our experimental evaluation showed that the cancer region segmentation and lymphocyte classification models achieved
very good performance with respect to the F1-score, accuracy, and AUC metrics and performed better than the previous
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Method F1-score Accuracy AUC
Saltz et al.32 0.770 74.9% 0.808
L-VGG16 0.891 88.4% 0.943
L-Resnet34 0.893 89.0% 0.950
L-Incepv4 0.879 87.5% 0.938
Table 4. Performance comparison of the Lymphocytes detection task between Saltz et al.32 and our models.
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Figure 2. Cancer and lymphocyte probability maps along with map of cancer and lymphocyte labels generated through
analysis of representative slides from Dtcga (A: TCGA-A2-A0CL-01Z-00-DX1, B: TCGA-A2-A04X-01Z-00-DX1, C:
TCGA-A2-A0CW-01Z-00-DX1). Figures in a given row are results generated from the WSI depicted in the first column.
Figures A-C depict WSIs with ground truth generated by our expert pathologist. Figures D-F depict the corresponding cancer
probability maps generated by our cancer detection models, C-Resnet34. Figures G-I depict the corresponding lymphocyte
probability maps generated by the Lymphocyte classification models, L-Resnet34. Figures J-L depict a combined heatmap of
cancer and lymphocytes. Invasive breast cancer detection denoted in yellow with superimposed lymphocyte detection denoted
in red. The legends of figures J-L are L, C, and T which refer to lymphocyte, cancer, and tissue region, respectively.
models. We applied the best of these models to 1,015 TCGA invasive breast cancer WSIs and generated Tumor, TIL, and
combined Tumor-TIL maps. We will make these maps publicly available (please see "Data Availability" section). Figure 2
shows example Tumor-TIL combined maps overlaid on WSIs and as heatmaps. The figure visualizes the spatial relationships
between lymphocytes and tumor regions. The lymphocyte patches in these examples WSIs show TILs and tumor-associated
lymphocytes (TALs) that surround the cancer regions. These visual representations of TILs, TALs, and cancer regions provide
valuable information for further analyses.
Discussion
Studies have shown tumor-infiltrating lymphocytes (TILs) can be used as a biomarker to predict clinical outcomes, including
treatment response, in invasive breast cancer patients 9–11. With the emergence of immunotherapy in breast cancer, the
evaluation of the concentration of TILs as a readily available biomarker. As shown in Figure 3, the cancer detection algorithm
shows that the cancer region occupies approximately 50-60% of the total tissue area in the WSI. The lymphocyte detection
algorithm shows high probability areas with TILs. The tumor-TIL method provides insight about scattered TILs that occupy
approximately 20-30% of the cancer region, consistent with a low TIL% categorization with additional spatial information that
shows a sparse multi-focal distribution. Combined breast cancer tumor-TIL maps like the one shown in this example have been
generated for 1,015 TCGA breast cancer WSIs and will be made publicly available in our custom web-based application.
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Figure 3. Enlarged example of a cancer and lymphocyte probability map and cancer along with map of cancer and
lymphocyte labels for TCGA WSI (case ID: TCGA-E9-A248-01Z-00-DX1) generated by our algorithms, C-Resnet34 and
L-Resnet34. A: WSI of an invasive breast cancer H&E tissue section. The viable tumor region is annotated by a pathologist
with a red line. B and C are lymphocyte probability map and cancer probability map predicted by our algorithm, respectively.
The probabilities are in range from 0 to 1. D: Invasive breast cancer detection denoted in yellow with superimposed lymphocyte
detection denoted in red. Grey areas outside of the yellow tumor region denote non-tumor connective and adipose tissues.
The evaluation of TILs in invasive breast cancer is likely to expand due to the accumulating evidence showing how TILs
can be used to predict treatment response in the settings of neoadjuvant and adjuvant chemotherapy. However, the routine
evaluation of TILs has not achieved widespread adoption even though the established methodology by the International
Immuno-Oncology Biomarker Working Group18 is relatively straightforward, uncomplicated, and based on the examination
of TILs on standard H&E-stained tissue sections. Figure 3 readily identifies TILs and a focal area with peritumoral TALs
as a surrogate computational biomarker that is similar to how IHC is routinely utilized by pathologists to highlight cells and
structures. However, IHC is not routinely performed to identify and classify subsets of TILs in breast cancer due to the time
constraints of pathologists, desire to preserve diagnostic tissue, and additional costs, whereas this kind of insight can be made
readily available in a low-cost and scalable manner to achieve the goals of the International Immuno-Oncology Biomarker
Working Group. With emerging methods like our breast cancer tumor-TIL detection tool, pathologists will be able to add the
evaluation of TILs to the standard IHC panel to determine ER, PR, HER2 expression status.
In previous work, several research groups carried out image analyses focused on detection of metastatic breast cancer38–40
and mitosis41–43 using highly curated but relatively small datasets from algorithm evaluation challenges24–27. Cruz-Roa et al.
2017 and 201828, 29 used deep learning approaches for detecting invasive breast cancer in WSIs. The deep learning models were
trained using WSIs from the Hospital of the University of Pennsylvania (HUP) and from University Hospitals Case Medical
Center/Case Western Reserve University (UHCMC/CWRU) and evaluated with 195 WSIs from TCGA. Kwok30 and Dong et
al.31 proposed methods to classify breast cancer regions in WSIs using datasets provided by the ICIAR2018 Grand Challenge
on Breast Cancer Histology Images27. The ICIAR2018 dataset contains 2 subsets of training data: Part A consists of 400
images of 2048×1536 pixels at 0.42 µm×0.42 µm resolution and Part B is made up 10 WSIs with manual annotations from
pathologists. Kwok30 implemented a 2-stage training approach where a basic CNN network is trained in the first stage to mine
hard examples on data from part B. These examples were then used to train a deep learning model in the second stage. Dong et
al.31 employed deep reinforcement learning to decide whether regions of interest should be processed for segmentation at high
or low image resolutions. Most recently, Amgad, M. et al., 201944 proposed a fully convolutional framework for semantic
segmentation of histology images via structured crowdsourcing. This was the first work using crowdsourcing in pathology
task which involved a total of 25 participants at different expertise levels from medical students to expert pathologists to
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generate training data for a deep learning algorithm. The authors solely focused on segmenting triple-negative breast cancer
(TNBC), an aggressive genomic subtype that comprises ∼15% of breast cancer cases, into five distinct classes: Tumor, Stroma,
Inflammatory Infiltration, Necrosis and Other. Using a training dataset of 151 representative region of interests (ROI, mean ROI
size of 1.18mm2) selected from 151 H&E TCGA WSIs with detailed curated annotations, a fully convolutional VGG16-FCN-8
network was able to achieve an AUC of 0.941 for Tumor region.
The current methods for assessing TILs in individual patients are still subjective, laborious, and may be difficult to quantify.
More rigorous, objective, and efficient methods are needed. This is especially true for precision medicine applications since the
tumor microenvironment in breast cancer is heterogeneous and composed of malignant cells, premalignant lesions, adjacent
normal tissue, stroma, immune cell infiltrates, vessels, nerves, and fat. Therefore, to help further our understanding of breast
cancer biology for research and clinical applications, we developed a tumor-TIL spatial mapping tool to automatically detect
breast cancer in H&E stained WSIs to quantitatively estimate and characterize the relationship between tumor cells and TILs.
In the current state, the breast tumor-TIL maps can be used to identify spatial patterns of distributions of TILs within intra-
and peritumoral regions of invasive cancer, as well as lymphocyte infiltrates in adjacent tissues beyond the borders of the
tumor. This tool can also be adapted for practical uses that include improving the reproducibility and precision in reporting
tumor size and features of the tumor boundary for radiologic-pathologic correlation. As a potential clinical application to
quantify TILs and identify spatial patterns of distribution of TILs, this tool can help guide management and select treatment in
conjunction with existing molecular subtyping platforms to predict survival and recurrence since TILs are being shown to be
reliable prognostic and predictive biomarkers in invasive breast cancer. Another potential application of this tool is to screen
candidates who may benefit from immunotherapy in primary, refractory, and recurrent disease since such treatments are not
expected to be useful if a significant amount and distribution of TILs are not present.
Most existing software algorithms for TILs assessments are proprietary, expensive, and cannot be customized by the user.
Therefore, we are making our invasive breast cancer TCGA tumor-TIL dataset publicly available with an interface to visually
interact with the data. The interface permits quantification of TILs in tumor areas and the ability to rapidly spot check and
evaluate true-positive and false-positive predictions by the deep learning models. The invasive breast cancer TCGA-TIL maps
are displayed side-by-side with an interactive H&E slide viewer to permit a high level of exploration within the entire data
set. We also intend to further combine this tumor-TIL method to characterize tumor immune heterogeneity and spatially
characterize local patterns of the lymphocytic infiltrate in different parts of the tumor, e.g. center of the tumor, invasive
margins, and metastases. The tumor-TIL heatmaps can also be combined with other types of digital pathology-based image
analyses that extract object-level of information, such as size, shape, color, texture, etc. (collectively known as Pathomics), to
generate an unprecedented quantitative examination of invasive breast cancer. Such analytic data can complement traditional
histopathologic evaluation that can be correlated with clinical information, radiologic imaging, molecular studies, survival, and
treatment response. We believe that the availability of Tumor-TIL maps along with software that allows interactive viewing
of the computational analysis will improve reproducibility and precision in reporting tumor size, tumor boundary features,
TILs assessment, and extraction of relevant nuclear and cellular features. These improvements will in turn enhance clinical and
pathology decision support in guiding management, treatment selection, and predicting survival and recurrence, in conjunction
with existing molecular subtyping platforms.
The need to quantify spatial inter-relationships between tumor regions and infiltrating lymphocytes is becoming increasingly
important in invasive breast cancer. Tumor-TIL maps generated from H&E images can be employed to carry out a wide
range of correlative studies in the context of clinical trials, epidemiological investigations, and surveillance studies. Our
methods leverage open source convolutional neural networks; the programs we have developed are also being made public and
freely available. The results of this effort is a reliable and robust methodology, datasets, and programs that can be employed
to carry out tumor-TIL analyses for 1,015 TCGA breast cancer WSIs. In future studies, we will further refine this tool to
differentiate between invasive and in situ premalignant lesions and explore methods that can facilitate faster predictions for
practical real-time clinical applications.
Methods
Ethics Statement
The WSI from SEER came from a larger pilot program examining the feasibility of and best practices for the virtual tissue
repository (VTR), which included WSI (VTR Pilot). As all data in the VTR Pilot, including the whole slide images, were
deidentified prior to receipt by the NCI SRP, the NIH Office of Human Subjects Research Protection determined that the study
was excluded from NIH IRB review. The SEER registries supplying the deidentified WSIs each obtained IRB approval from
their respective institution(s). The Stony Brook IRB has classified the dataset as being a non-human subjects research dataset.
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Figure 4. Annotation example from pathologist (Figures A and B) and image patches extracted from WSIs. Red lines in
figures A and B were manually drawn by expert pathologist to enclose the cancer regions. Regions outside the annotated
regions are non-cancer regions. Patches surrounded in red boxes are positive samples which contain invasive cancer cells.
Patches surrounded in green boxes are negative samples which do not contain invasive cancer cells.
Patch Extraction for the Breast Cancer Dataset
We extracted image patches at the highest image resolution within and outside the segmented cancer regions using an open
source library called OpenSlide45. Patches with a size of 350×350 pixels at 400x magnification (equivalent to 88 µm×88 µm)
resulted in the best classification performance and were used to create the training datasets. Each patch was labeled positive
(i.e., it intersected or was in a cancer/tumor region) or negative (i.e., it was outside cancer/tumor regions). Figure 4 shows an
example of the pathologist’s annotations. The region inside the red line represents the cancer region. The figure also shows the
sample patches extracted from the cancer and non-cancer regions. We trained the cancer detection models with patches from
the SEER data. In order to compare our results, we evaluated the models on a publicly dataset consisted of 195 TCGA WSIs
provided in Cruz-Roa et al.29.
Previous work has shown that it is beneficial to have more negative samples than positive samples in a training dataset
for image classification in digital pathology29, 46–48. A good ratio of negative to positive samples (i.e., patches in our case)
will increase the generalization of a CNN model and decrease false positive rate. We experimented with a range of ratios of
negative patches to positive patches with the same validation dataset. The details of the training, validation, and test datasets are
presented in Table 1.
Convolutional Neural Networks
We investigated multiple state-of-the-art deep learning architectures for the task of classifying cancer regions and lymphocyte
regions in WSIs. Considering both the computational complexity and the capacity of different neural networks, we used
three CNN architectures: the VGG 16-layer34, the Resnet 34-layer35, and the Inception-v4 network36. These models are
state-of-the-art CNN architectures which are widely used in a range of application domains. Earlier work49, 50 showed that
refining a CNN pre-trained on the ImageNet dataset51 is a good approach to boosting image classification performance in
digital pathology. In our work, we refined the pre-trained CNN models with our training data. We implemented the CNN
networks using pyTorch 0.437.
The VGG16 and Resnet34 were designed to process 224×224-pixel patches whereas the Inception-v4 accepts 299×299-
pixel image patches. Since our dataset consists of 350×350-pixel patches at 400x magnification, input patches were resized
to the desired input size for each network. In addition, for Resnet34 and Inception-v4, we changed the dimension of the
output layer from 1,000 classes to two classes for our binary classification problem. For VGG16, we reduced the size of the
intermediate features of the classification layer from 4,096 to 1,024 and only kept the first four layers in the classification
layer. This modification reduced the number of trainable parameters of this network from 138 Millions to 41 Millions. Our
modifications to the classification layers of the CNN architectures are presented in Table 5.
The Lymphocyte training datasets contain 100×100-pixel patches at 200x magnification. We resized the input 100×100-
pixel patches to 200×200-pixel patches for the Lymphocyte classification CNNs.
We used the same training procedure for all of the networks. At the beginning of the training, the weights of the networks
were initially fixed except for the classification layer. The networks were trained in this state for N epochs (N is three for the
Cancer models and N is five for the Lymphocyte models) with a batch size of B (B is 256 for the Cancer models and B is 128
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VGG16 Resnet34 Inception-v4
Original Modified Original Modified Original Modified
Linear(25088,4096) Linear(25088,1024) Linear(512,1000) Linear(512,2) Linear(1536,1000) Linear(1536,2)
ReLU −→ Dropout ReLU −→ Dropout
Linear(4096,4096) Linear(1024,2)
ReLU −→ Dropout
Linear(4096,1000)
Table 5. Modifications to the classification layers of the CNNs
for the Lymphocyte models) , an initial learning rate of 0.01, a momentum of 0.9 and a weight decay of 0.0001. After N epochs,
the training process enabled updates to the initially fixed weights. The network was then trained for total of 20 epochs, updating
all the weights. The training process used a stochastic gradient descent method52 in order to minimize a cross entropy loss
function.
The color profiles of WSIs may vary from image to image because of variations in staining and image acquisition53–55. We
used data augmentation to reduce the effects of color/intensity variability and data acquisition artifacts. The data augmentation
operations included random rotation between 0 and 22.5 degrees, random vertical and horizontal flipping, perturbations in
patch brightness, contrast, saturation, and normalization of R,G, and B channels to a mean of 0.0 and standard deviation of 1.0.
In the prediction (test) phase, no data augmentation was applied except for the normalization of the color channels. Each
patch was assigned a predicted classification probability value between 0.0 and 1.0 by the trained model, indicating the
probability of a patch being positive. This value is thresholded to generate the final class label of each patch.
Post-processing Step for Cancer Heatmaps
Most patch-based classification algorithms56, 57 predict the label of a patch independent of other patches in an image. They do
not take into account the characteristics and labels of neighbor patches. Invasive cancer regions in breast cancer tend to be close
to each other. In other words, the probability of a patch to be positive is correlated to its surrounding patches. To incorporate
this information in our analysis pipeline, we employed a simple, yet effective, aggregation approach as a post-processing step.
This approach takes per-patch classification probability values, converts them into a probability map, called H, and produces
an aggregated probability map, called A. The classification probability value of a patch in A is computed by an aggregation
operation over neighbor patches within a specific distance of the patch in H. The relationship between the aggregated probability
map A and H can be formulated as follows:
A(i, j) = f
({
H(m,n)
∣∣m ∈ [⌊ i
w
⌋
w,
(⌊ i
w
⌋
+1
)
w
]
,n ∈
[⌊
j
w
⌋
w,
(⌊ j
w
⌋
+1
)
w
]})
(1)
Here, H(m,n) is the probability values of a patch at location (m,n) of the original probability map. Similarly, A(i, j) is the
probability value of the aggregated patch at location (i, j) computed by the aggregation operation. f is the aggregation function
over a set of patches in a window of
[⌊ i
w
⌋
w,
(⌊ i
w
⌋
+1
)
w
]×[⌊ jw⌋w,(⌊ jw⌋+1)w], and w is the window size. In our aggregation
approach, all patches within the window will have the same prediction score after the aggregation operation. bxc is the
Floor operation which takes x as an input and returns the largest integer that is less than or equal to x. We explored different
aggregation function such as Average, Median, and Max. The experiments were carried out using Tseer. The best aggregation
method from these experiments was used to generate aggregated probability maps for Ttcga. Empirically, we have found that
the Max function and a window of 4x4 resulted in the best performance on the Tseer. Hence, we applied these settings for the
post-processing step on the Ttcga WSIs.
Combined Tumor-TIL Maps
We merged each pair of cancer and lymphocyte heatmaps into a single heatmap as an RGB image. The R channel stores
the lymphocyte probabilities quantized to 0-255; the G channel stores the cancer probabilities quantized to 0-255; and the B
channel stores if a patch is tissue or glass background.
Software Tools for Data Management and Visualization
Engaging multivariate analysis of digital pathology data in a manner that is transparent to the domain expert has always been
challenging due to the size of whole slide images. A typical digitized whole slide image (WSI), at 400x magnification, is 1-4
GBs in size. A modest cohort of a hundred patients (approximately two slides per patient) can easily result in 0.5-1 TBs of
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Figure 5. User interface of our web-based application to study the spatial relationship between cancer regions and lymphocyte
regions. Figure on the left shows the TILs heatmap where invasive breast cancer detection denoted in yellow with
superimposed lymphocyte detection denoted in red. Figure on the right is the caMicroscope33 that displays the regions of the
WSI. Users can click on the TILs map to zoom in the corresponding regions on the caMicroscope.
image data. Processing, analyzing, and visualizing data of this size is a non-trivial task. Various image processing and analysis
methods, including deep learning based classifiers, are used to generate high-level representations (eg., areas of an image with a
high probability of being tumor) and low-level representations (eg., segmented nuclei). The examination of these results and
their representations requires their interactive interrogation and visual analytic tools that link these representations with the
underlying images as well as associated clinical, demographic, and molecular data. We have developed a portable FeatureMap
web-based application that combines cached calling to a data-intensive backend (PathDB - https://github.com/SBU-BMI/pathdb)
with a browser-based multivariate visualization library that is sufficiently lightweight to run on a mobile device. We employed
the FeatureMap application to host and visualize TILs maps of 1,015 TCGA invasive breast cancer cases. PathDB is integrated
with our pathology viewer, caMicroscope33, that allows users to click on parts of a TIL Map, zoom-in on the corresponding
region on the WSI image, and interactively examine interesting areas of the TIL Map. Users can also freely move to any
region in the WSI by dragging the cursor and zoom in or zoom out by scrolling the mouse. Readers are welcome to try our
application at https://mathbiol.github.io/tcgatil/. Figure 5 shows a screenshot of our web-based application. Technical details of
FeatureMap will be provided in a separate paper.
An algorithm for processing and analysis of WSI has significant computational needs, often requiring multiple CPU cores,
large amounts of RAM, and one or more GPUs. Given the size of an individual image and the volume of data in a cohort,
the processing and analysis of WSI on a large scale are significant challenges. Cloud computing today affords researchers
with an unlimited pool of computing that is elastic, scalable, and provisioned on-demand. Our team has leveraged the cost
and computational advantages of cloud computing by deploying our various deep learning algorithms for computational
identification of TILs, similar algorithms for nuclear segmentation, tumor region segmentation, and characterizing and
quantifying other Pathomics features. The deep learning algorithms and associated methods to characterize features are
containerized using Docker and then deployed as workflows on the Google Cloud. The workflows are represented using the
Workflow Description Language58 and orchestrated on the cloud behind APIs. This pathway also allows us to disseminate
algorithms and workflows with other researchers without requiring extensive installation or software maintenance, while users
only pay for the computing they use to run the algorithms. A detailed description of our cloud-based algorithm management
and dissemination system will be provided in a separate paper.
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Data Availability
The SEER images used in the training dataset were gathered in a work carried out with the SEER consortium and will be
made publicly available in the future as part of a separate pilot project. The invasive breast cancer images are publicly
available and provided by TCGA ( http://cancergenome.nih.gov/ and the Genomic Data Commons (GDC) Data Portal in
https://portal.gdc.cancer.gov/ ).
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